27 July 2022
: Case report 
Hypoprothrombinemia During Cefmetazole Treatment: A Case Report
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Yuichiro Haba1ABCDEF*, Hikaru Akizuki2ABCDEF, Naoyuki Hashiguchi2ADEF, Toshio Naito
1ADEF
DOI: 10.12659/AJCR.936712
Am J Case Rep 2022; 23:e936712
Table 3. Naranjo scale of adverse drug reaction probability. Underlining is applied for our study.
| Questionnaire | Yes | No | Do not know or not done | |
|---|---|---|---|---|
| 1. Are there previous conclusive reports of this reaction? | 0 | 0 | ||
| 2. Did the adverse event appear after the drug was given? | −1 | 0 | ||
| 3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? | 0 | 0 | ||
| 4. Did the adverse reaction reappear upon readministering the drug? | −1 | |||
| 5. Were there other possible causes for the reaction? | −1 | 0 | ||
| 6. Did the adverse reaction reappear upon administration of placebo? | −1 | +1 | ||
| 7. Was the drug detected in the blood or other fluids in toxic concentrations? | +1 | 0 | ||
| 8. Was the reaction worsened upon increasing the dose? Or, was the reaction lessened upon decreasing the dose? | +1 | 0 | ||
| 9. Did the patient have a similar reaction to the drug or a related agent in the past? | +1 | 0 | ||
| 10. Was the adverse event confirmed by any other objective evidence? | 0 | 0 | ||
| Total score in our study | 7 | |||
| ≥9: definite adverse drug reaction1–4: possible adverse drug reaction0: doubtful adverse drug reaction | ||||